In Vitro Activity of Colistin (Polymyxin E) against 3,480 Isolates of Gram-Negative Bacilli Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007-2008

被引：58
作者：
Walkty, A. [1 ,2 ]
DeCorby, M. [3 ]
Nichol, K. [1 ,2 ]
Karlowsky, J. A. [1 ,2 ,3 ]
Hoban, D. J. [1 ,2 ,3 ]
Zhanel, G. G. [1 ,2 ,3 ]
机构：
[1] Univ Manitoba, Hlth Sci Ctr, Dept Clin Microbiol, Winnipeg, MB R3A 1R9, Canada
[2] Univ Manitoba, Hlth Sci Ctr, Dept Med, Winnipeg, MB R3A 1R9, Canada
[3] Univ Manitoba, Fac Med, Dept Med Microbiol, Winnipeg, MB R3A 1R9, Canada
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2009年 / 53卷 / 11期
关键词：
ACINETOBACTER-BAUMANNII; BACTERIAL-INFECTIONS; INTRAVENOUS COLISTIN; EFFICACY; THERAPY; SAFETY; SODIUM;
D O I：
10.1128/AAC.00786-09
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of colistin was evaluated versus 3,480 isolates of gram-negative bacilli using CLSI broth microdilution methods. The MIC(90) of colistin was <= 2 mu g/ml against a variety of clinically important gram-negative bacilli, including Escherichia coli, Klebsiella spp., Enterobacter spp., Acinetobacter baumannii, and Pseudomonas aeruginosa. All multidrug-resistant (n = 76) P. aeruginosa isolates were susceptible to colistin (MIC, <= 2 mu g/ml). These data support a role for colistin in the treatment of infections caused by multidrug-resistant P. aeruginosa.
引用
收藏
页码：4924 / 4926
页数：3
相关论文
共 13 条
[1]  
[Anonymous], 2012, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard
[2]   A reassessment of the in-vitro activity of colistin sulphomethate sodium [J].
Catchpole, CR ;
Andrews, JM ;
Brenwald, N ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) :255-260
[3]  
Clinical and Laboratory Standards Institute, 2008, M100S18 CLSI
[4]   Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections [J].
Falagas, ME ;
Kasiakou, SK .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) :1333-1341
[5]   Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) [J].
Gales, AC ;
Jones, RN ;
Sader, HS .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (04) :315-321
[6]   Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:: A comparison with imipenem-susceptible VAP [J].
Garnacho-Montero, J ;
Ortiz-Leyba, C ;
Jiménez-Jiménez, FJ ;
Barrero-Alodóvar, AE ;
García-Garmendia, JL ;
Bernabeu-Witteli, M ;
Gallego-Lara, SL ;
Madrazo-Osuna, J .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1111-1118
[7]   Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU [J].
Kallel, Hatem ;
Bahloul, Mabrouk ;
Hergafi, Leila ;
Akrout, Malek ;
Ketata, Wajdi ;
Chelly, Hedi ;
Ben Hamida, Chokri ;
Rekik, Noureddine ;
Hammami, Adnane ;
Bouaziz, Mounir .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 (04) :366-369
[8]   Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand [J].
Koomanachai, Pornpan ;
Tiengrim, Surapee ;
Kiratisin, Pattarachai ;
Thamlikitkul, Visanu .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (05) :402-406
[9]   Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections [J].
Li, Jian ;
Nation, Roger L. ;
Turnidge, John D. ;
Milne, Robert W. ;
Coulthard, Kingsley ;
Rayner, Craig R. ;
Paterson, David L. .
LANCET INFECTIOUS DISEASES, 2006, 6 (09) :589-601
[10]   Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients [J].
Markou, N ;
Apostolakos, H ;
Koumoudiou, C ;
Athanasiou, M ;
Koutsoukou, A ;
Alamanos, I ;
Gregorakos, L .
CRITICAL CARE, 2003, 7 (05) :R78-R83
12